查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856968

全球神经退化性疾病市场：预测至 2032 年—按分子类型、适应症、药物类别、给药途径、最终使用者和地区进行分析

Neurodegenerative Disease Market Forecasts to 2032 - Global Analysis By Molecule Type (Small-Molecule Drugs, Biologics and Cell & Gene Therapies), Indication, Drug Class, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球神经退化性疾病市场规模将达到 644 亿美元，到 2032 年将达到 1,189 亿美元，预测期内复合年增长率为 9.15%。

神经退化性疾病是指一组以神经细胞结构和功能逐渐丧失为特征的疾病，最终导致神经细胞逐渐死亡。这些疾病会影响大脑和神经系统，损害认知、运动和感觉功能。常见的例子包括阿兹海默症、帕金森氏症、亨廷顿氏症和肌萎缩性侧索硬化症（ALS）。其根本原因通常涉及异常蛋白质累积、基因突变、氧化压力和粒线体功能障碍。由于神经细胞无法有效再生，这些疾病通常会发展为慢性病，并随着时间的推移而恶化。由于其复杂性和缺乏有效治疗方法，神经退化性疾病为医学和社会带来了重大挑战。

生物标记和诊断技术的进步

研究人员正在开发体液和影像生物标记，以识别阿兹海默症、帕金森氏症和肌萎缩侧索硬化症（ALS）的早期病理。人工智慧和机器学习的结合正在提高诊断准确性和疾病分层能力。製药公司正在利用生物标记来优化试验设计和治疗标靶。伴随诊断在精准神经病学研发管线中正变得越来越普遍。这些能力正在推动早期疗育和个人化医疗领域的创新。

复杂疾病生物学与异质性

许多疾病的病因复杂，涉及遗传、环境和发炎等多种因素。疾病进展在个体间差异很大，这使得临床试验终点和治疗效果的评估变得复杂。临床前研究因缺乏经过验证的动物模型和转化生物标记而受阻。监管机构要求提供在异质人群中疗效和安全性的有力证据。这些挑战持续阻碍药物研发和平台规模化应用。

医疗保健支出和意识不断提高

各国政府正在资助国家失智症战略和老化相关研究计画。旨在消除认知衰退和神经系统疾病污名化的宣传活动正在进行中。医院正在扩大记忆诊所和神经復健中心，以满足日益增长的需求。对数位医疗和远端监测的投资正在支持长期护理和疾病管理。这些趋势正在推动预防、诊断和治疗创新领域的发展。

资源匮乏地区诊断途径有限

许多地区缺乏训练有素的神经科、影像基础设施和分子检测能力。农村和医疗服务不足的人面临诊断延迟和专科诊疗机会有限的问题。 PET扫描、脑脊髓液检测和基因检测的费用和可近性仍然是新兴市场的障碍。转诊途径分散和公众认知度低进一步损害了医疗品质。这些限制因素持续阻碍全球神经退化领域的公平性和治疗效果。

新冠疫情的影响：

疫情扰乱了全球神经退化患者的临床试验、诊断和长期照护。封锁和资源重新分配减缓了患者获得治疗和疾病监测的速度。然而，疫情后的復苏策略强调神经科照护的韧性和数位转型。远端医疗、远距认知评估和数位生物标记已在老年族群中广泛应用。疫情期间，民众对神经系统健康的关注度有所提高，这影响了政策和研究重点。这些转变正在加速对基础设施、技术创新和以患者为中心的护理模式的投资。

预计在预测期内，阿兹海默症细分市场将成为最大的细分市场。

由于阿兹海默症领域将占据最大的市场份额。製药公司已推出针对淀粉样蛋白和Tau蛋白病理的单株抗体和疾病修正治疗。随着人口老化，对早期检测和风险分层的投资正在增加。与数位认知工具和体液生物标记的整合正在改善筛检和监测。各国政府正在资助失智症研究和护理协调计画。

预计细胞和基因治疗领域在预测期内将达到最高的复合年增长率。

随着治疗方法在罕见和进行性神经退化性疾病中的应用日益广泛，细胞和基因治疗领域预计将在预测期内呈现最高的成长率。研发人员正利用病毒载体、干细胞和基因编辑平台来恢復神经元功能并阻止疾病进展。监管机构正在为突破性疗法提供快速审查和有条件核准。对生产规模化和递送平台的投资正在提高治疗的准备度和可负担性。生物技术公司、医院和支付方之间的伙伴关係正在支持治疗的可及性和报销模式。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的研究基础设施、积极的监管参与以及人口老化趋势。美国和加拿大拥有众多领先的神经病学中心、临床试验网络和患者权益组织。美国食品药物管理局（FDA）的快速通道和突破性疗法认定等项目为创新和市场准入提供了支持。对生物标记开发和精准神经病学的投资正在推动平台扩张。领先的生物技术公司和学术机构的存在进一步巩固了其市场领导地位。

复合年增长率最高的地区：

预计亚太地区在预测期内将呈现最高的复合年增长率，这主要得益于医疗现代化、人口老化和政策改革的共同推动。中国、日本、印度和韩国等国家正在扩大都市区地区神经系统疾病诊断和治疗的覆盖范围。政府支持的计画正在推动失智症筛检、公众意识提升和基础设施建设。区域生物技术公司正在推出针对特定族群适应症的细胞和基因疗法。公共和私人医疗系统对经济实惠且扩充性的解决方案的需求日益增长。这些趋势正在推动整个神经退化性疾病生态系统的区域性成长。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球神经退化性疾病市场（依分子类型划分）

  • 小分子药物
  • 生技药品
  • 细胞和基因治疗

6. 全球神经退化性疾病市场（依适应症划分）

  • 阿兹海默症
  • 帕金森氏症
  • 亨丁顿舞蹈症
  • 肌萎缩侧索硬化症（ALS）
  • 多发性硬化症（MS）
  • 脊髓性肌肉萎缩症（SMA）
  • 其他迹象

7. 全球神经退化性疾病药物市场

  • N-甲基-D-天门冬胺酸（NMDA）受体拮抗剂
  • 选择性血清素再回收抑制剂（SSRIs）
  • 多巴胺促效剂和抑制剂
  • 胆碱酯酶抑制剂
  • 单株抗体
  • 基因和RNA治疗方法
  • 其他药物类别

8. 全球神经退化性疾病市场（依给药途径划分）

  • 口服
  • 注射
  • 经皮
  • 鼻内

9. 全球神经退化性疾病市场（依最终用户划分）

  • 医院和诊所
  • 研究和学术机构
  • 製药和生物技术公司
  • 患者权益倡导组织
  • 其他最终用户

10. 全球神经退化性疾病市场（依地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章：公司简介

  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Biogen Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Eisai Co., Ltd.
  • Lundbeck A/S
  • Denali Therapeutics Inc.
Product Code: SMRC31832

According to Stratistics MRC, the Global Neurodegenerative Disease Market is accounted for $64.4 billion in 2025 and is expected to reach $118.9 billion by 2032 growing at a CAGR of 9.15% during the forecast period. Neurodegenerative disease refers to a group of disorders characterized by the progressive loss of structure or function of neurons, leading to their gradual death. These conditions affect the brain and nervous system, impairing cognitive, motor, and sensory functions. Common examples include Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The underlying causes often involve abnormal protein accumulation, genetic mutations, oxidative stress, and mitochondrial dysfunction. As neurons cannot regenerate efficiently, these diseases are typically chronic and worsen over time. Neurodegenerative diseases pose significant medical and social challenges due to their complexity and lack of curative treatments.

Market Dynamics:

Driver:

Advances in biomarker & diagnostic technology

Researchers are developing fluid-based and imaging biomarkers to identify early-stage pathology in Alzheimer's, Parkinson's, and ALS. Integration with AI and machine learning is improving diagnostic accuracy and disease stratification. Pharmaceutical companies are using biomarkers to optimize trial design and therapeutic targeting. Companion diagnostics are gaining traction across precision neurology pipelines. These capabilities are propelling innovation in early intervention and personalized care.

Restraint:

Complex disease biology & heterogeneity

Many conditions involve multifactorial pathogenesis, including genetic, environmental, and inflammatory components. Disease progression varies widely across individuals, complicating trial endpoints and treatment response. Lack of validated animal models and translational biomarkers slows preclinical research. Regulatory bodies require robust evidence for efficacy and safety in heterogeneous populations. These challenges continue to hinder drug development and platform scalability.

Opportunity:

Rising healthcare spending & awareness

Governments are funding national dementia strategies and aging-related research programs. Public campaigns are improving awareness and reducing stigma around cognitive decline and neurological disorders. Hospitals are expanding memory clinics and neurorehabilitation centers to meet rising demand. Investment in digital health and remote monitoring is supporting long-term care and disease management. These trends are fostering growth across prevention, diagnosis, and therapeutic innovation.

Threat:

Limited diagnostic access in low-resource settings

Many regions lack trained neurologists, imaging infrastructure, and molecular testing capabilities. Rural and underserved populations face delays in diagnosis and limited access to specialized care. Cost and availability of PET scans, CSF assays, and genetic testing remain barriers in emerging markets. Fragmented referral pathways and low public awareness further degrade care quality. These constraints continue to hamper equity and outcomes across global neurodegenerative ecosystems.

Covid-19 Impact:

The pandemic disrupted clinical trials, diagnostics, and long-term care for neurodegenerative patients worldwide. Lockdowns and resource reallocation delayed therapy access and disease monitoring. However, post-pandemic recovery strategies have emphasized resilience and digital transformation in neurology care. Telemedicine, remote cognitive assessments, and digital biomarkers gained traction across aging populations. Public awareness of neurological health increased during the crisis, influencing policy and research priorities. These shifts are accelerating investment in infrastructure, innovation, and patient-centric care models.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period due to its high prevalence, diagnostic complexity, and therapeutic innovation. Pharmaceutical firms are launching monoclonal antibodies and disease-modifying therapies targeting amyloid and tau pathology. Investment in early detection and risk stratification is rising across aging populations. Integration with digital cognitive tools and fluid biomarkers is improving screening and monitoring. Governments are funding dementia research and care coordination programs.

The cell & gene therapies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell & gene therapies segment is predicted to witness the highest growth rate as curative approaches gain traction across rare and progressive neurodegenerative conditions. Developers are using viral vectors, stem cells, and gene editing platforms to restore neuronal function and halt disease progression. Regulatory bodies are offering expedited review and conditional approvals for breakthrough therapies. Investment in manufacturing scale-up and delivery platforms is improving readiness and affordability. Partnerships between biotech firms, hospitals, and payers are supporting access and reimbursement models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research infrastructure, regulatory engagement, and aging demographics. The United States and Canada host major neurology centers, clinical trial networks, and patient advocacy organizations. FDA programs such as Fast Track and Breakthrough Therapy Designation are supporting innovation and market entry. Investment in biomarker development and precision neurology is driving platform expansion. Presence of leading biotech firms and academic institutions is reinforcing leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, aging populations, and policy reform converge. Countries like China, Japan, India, and South Korea are scaling neurology diagnostics and therapy access across urban and rural regions. Government-backed programs are supporting dementia screening, public awareness, and infrastructure development. Regional biotech firms are launching cell and gene therapies tailored to population-specific indications. Demand for affordable and scalable solutions is rising across public and private healthcare systems. These trends are accelerating regional growth across neurodegenerative disease ecosystems.

Key players in the market

Some of the key players in Neurodegenerative Disease Market include AbbVie Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., Biogen Inc., Eli Lilly and Company, Johnson & Johnson, Eisai Co., Ltd., Lundbeck A/S and Denali Therapeutics Inc.

Key Developments:

In January 2025, AbbVie exercised its first opt-in under the collaboration with Capsida Biotherapeutics, securing rights to a gene therapy program for neurodegenerative diseases. The decision followed promising primate data showing effective delivery of AbbVie's therapeutic payload to the brain using Capsida's engineered AAV capsids, while minimizing off-target effects in the liver and dorsal root ganglia.

In September 2023, Amneal launched IPX203 in the U.S. following FDA approval for Parkinson's disease. The extended-release formulation demonstrated superior "on-time" versus immediate-release carbidopa-levodopa in Phase 3 trials, offering improved symptom control and dosing convenience for patients with advanced Parkinson's.

Molecule Types Covered:

  • Small-Molecule Drugs
  • Biologics
  • Cell & Gene Therapies

Indications Covered:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)
  • Spinal Muscular Atrophy (SMA)
  • Other Indications

Drug Classes Covered:

  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Dopamine Agonists & Inhibitors
  • Cholinesterase Inhibitors
  • Monoclonal Antibodies
  • Gene & RNA-Based Therapies
  • Other Drug Classes

Route of Administrations Covered:

  • Oral
  • Injectable
  • Transdermal
  • Intranasal

End Users Covered:

  • Hospitals & Clinics
  • Research & Academic Institutes
  • Pharmaceutical & Biotech Companies
  • Patient Advocacy Groups
  • Other End-Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurodegenerative Disease Market, By Molecule Type

  • 5.1 Introduction
  • 5.2 Small-Molecule Drugs
  • 5.3 Biologics
  • 5.4 Cell & Gene Therapies

6 Global Neurodegenerative Disease Market, By Indication

  • 6.1 Introduction
  • 6.2 Alzheimer's Disease
  • 6.3 Parkinson's Disease
  • 6.4 Huntington's Disease
  • 6.5 Amyotrophic Lateral Sclerosis (ALS)
  • 6.6 Multiple Sclerosis (MS)
  • 6.7 Spinal Muscular Atrophy (SMA)
  • 6.8 Other Indications

7 Global Neurodegenerative Disease Market, By Drug Class

  • 7.1 Introduction
  • 7.2 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
  • 7.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
  • 7.4 Dopamine Agonists & Inhibitors
  • 7.5 Cholinesterase Inhibitors
  • 7.6 Monoclonal Antibodies
  • 7.7 Gene & RNA-Based Therapies
  • 7.8 Other Drug Classes

8 Global Neurodegenerative Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Injectable
  • 8.4 Transdermal
  • 8.5 Intranasal

9 Global Neurodegenerative Disease Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Research & Academic Institutes
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Patient Advocacy Groups
  • 9.6 Other End-Users

10 Global Neurodegenerative Disease Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Amneal Pharmaceuticals LLC
  • 12.3 Boehringer Ingelheim GmbH
  • 12.4 F. Hoffmann-La Roche Ltd.
  • 12.5 Merck & Co., Inc.
  • 12.6 Novartis AG
  • 12.7 Pfizer Inc.
  • 12.8 Teva Pharmaceutical Industries Ltd.
  • 12.9 UCB S.A.
  • 12.10 Biogen Inc.
  • 12.11 Eli Lilly and Company
  • 12.12 Johnson & Johnson
  • 12.13 Eisai Co., Ltd.
  • 12.14 Lundbeck A/S
  • 12.15 Denali Therapeutics Inc.

List of Tables

  • Table 1 Global Neurodegenerative Disease Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Neurodegenerative Disease Market Outlook, By Molecule Type (2024-2032) ($MN)
  • Table 3 Global Neurodegenerative Disease Market Outlook, By Small-Molecule Drugs (2024-2032) ($MN)
  • Table 4 Global Neurodegenerative Disease Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 5 Global Neurodegenerative Disease Market Outlook, By Cell & Gene Therapies (2024-2032) ($MN)
  • Table 6 Global Neurodegenerative Disease Market Outlook, By Indication (2024-2032) ($MN)
  • Table 7 Global Neurodegenerative Disease Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 8 Global Neurodegenerative Disease Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 9 Global Neurodegenerative Disease Market Outlook, By Huntington's Disease (2024-2032) ($MN)
  • Table 10 Global Neurodegenerative Disease Market Outlook, By Amyotrophic Lateral Sclerosis (ALS) (2024-2032) ($MN)
  • Table 11 Global Neurodegenerative Disease Market Outlook, By Multiple Sclerosis (MS) (2024-2032) ($MN)
  • Table 12 Global Neurodegenerative Disease Market Outlook, By Spinal Muscular Atrophy (SMA) (2024-2032) ($MN)
  • Table 13 Global Neurodegenerative Disease Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 14 Global Neurodegenerative Disease Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 15 Global Neurodegenerative Disease Market Outlook, By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (2024-2032) ($MN)
  • Table 16 Global Neurodegenerative Disease Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2024-2032) ($MN)
  • Table 17 Global Neurodegenerative Disease Market Outlook, By Dopamine Agonists & Inhibitors (2024-2032) ($MN)
  • Table 18 Global Neurodegenerative Disease Market Outlook, By Cholinesterase Inhibitors (2024-2032) ($MN)
  • Table 19 Global Neurodegenerative Disease Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 20 Global Neurodegenerative Disease Market Outlook, By Gene & RNA-Based Therapies (2024-2032) ($MN)
  • Table 21 Global Neurodegenerative Disease Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 22 Global Neurodegenerative Disease Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 23 Global Neurodegenerative Disease Market Outlook, By Oral (2024-2032) ($MN)
  • Table 24 Global Neurodegenerative Disease Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 25 Global Neurodegenerative Disease Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 26 Global Neurodegenerative Disease Market Outlook, By Intranasal (2024-2032) ($MN)
  • Table 27 Global Neurodegenerative Disease Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Neurodegenerative Disease Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 29 Global Neurodegenerative Disease Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 30 Global Neurodegenerative Disease Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 31 Global Neurodegenerative Disease Market Outlook, By Patient Advocacy Groups (2024-2032) ($MN)
  • Table 32 Global Neurodegenerative Disease Market Outlook, By Other End-Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.